By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Astrazeneca AB et al. v. Hetero Drugs, Ltd., Unit III et al.
3:11-cv-04468; filed August 2, 2011 in the District Court of New Jersey

• Plaintiffs:  Astrazeneca AB; Aktiebolaget Hassle; Astrazeneca LP; KBI Inc.; KBI-E Inc.
• Defendants:  Hetero Drugs, Ltd., Unit III; Hetero USA Inc.

Infringement of U.S. Patent Nos. 5,714,504 ("Compositions," issued February 3, 1988), 5,877,192 ("Method for the Treatment of Gastric Acid-Related Diseases and Production of Medication Using (-)Enantiomer of Omeprazole," issued March 2, 1999), and 6,875,872 ("Compounds," issued April 5, 2005), 6,369,085 ("Form of S-omeprazole," issued April 9, 2002) following a Paragraph IV certification as part of Hetero's filing of an ANDA to manufacture a generic version of AstraZeneca's Nexium® (esomeprazole magnesium, used for the treatment of gastroesophageal reflux disease).  View the complaint here.

Tibotec Inc. et al. v. Lupin Ltd. et al.
2:11-cv-04437; filed August 1, 2011 in the District Court of New Jersey

• Plaintiffs:  Tibotec Inc.; Tibotec Pharmaceuticals; G.D. Searle, LLC
• Defendants:  Lupin Ltd.; Lupin Pharmaceuticals Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.

Infringement of U.S. Patent Nos. 5,843,946 ("α- and β-Amino Acid Hydroxyethylamino Sulfonamides Useful as Retroviral Protease Inhibitors," issued December 1, 1998) and 6,248,775 (same title, issued June 19, 2001) following a Paragraph IV certification as part of Lupin's filing of an ANDA to manufacture a generic version of Tibotec's Prezista® (darunavir, used to treat human immunodeficiency virus (HIV-1) infection).  View the complaint here.

Pfizer Inc. et al. v. Hetero Drugs Ltd. et al.
2:11-cv-04372; filed July 28, 2011 in the District Court of New Jersey

• Plaintiffs:  Pfizer Inc.; Pfizer Ltd.; Pfizer Ireland Pharmaceuticals
• Defendants:  Hetero Drugs Ltd.; Hetero USA Inc.; Invagen Pharmaceuticals Inc.; Hetero Labs Ltd., Unit V.; Camber Pharmaceuticals Inc.

Infringement of U.S. Patent No. 6,469,012 ("Pyrazolopyrimidinones for the Treatment of Impotence," issued October 22, 2002) following a Paragraph IV certification as part of Hetero's filing of an ANDA to manufacture a generic version of Pfizer's Viagra® (sildenafil citrate, used to treat erectile dysfunction).  View the complaint here.